Spotlight on insulin glargine in type 1 and 2 diabetes mellitus

Treatments in Endocrinology

Volumn 1, Issue 1, 2002, Pages 55-58

  McKeage, Kate ^a   Goa, Karen L ^a  

^a ADIS INTERNATIONAL INC   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

GLUCOSE; HEMOGLOBIN A1C; INSULIN GLARGINE; ISOPHANE INSULIN; SOMATOMEDIN C;

CLINICAL TRIAL; DRUG ABSORPTION; DRUG EFFICACY; GLUCOSE BLOOD LEVEL; GLUCOSE HOMEOSTASIS; HUMAN; HYPOGLYCEMIA; INJECTION PAIN; INJECTION SITE; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PRIORITY JOURNAL; REVIEW;

DIABETES MELLITUS, TYPE 1; DIABETES MELLITUS, TYPE 2; HUMANS; HYPOGLYCEMIC AGENTS; INSULIN;

EID: 0038007359     PISSN: 11756349     EISSN: None     Source Type: Journal    
DOI: 10.2165/00024677-200201010-00006     Document Type: Review

References (38)

1. Bolli GB, Di Marchi RD, Park GD, et al. Insulin s and their potential in the management of diabetes mellitus. Diabetologia 1999 Oct; 42: 1151-67
2. Home P, Insulin glargine: the first clinically useful extended-acting insulin in half a century? Expert Opin Invest Drug 1999 Mar; 8: 307-14
3. Mohn A, Dunger DB. Insulin therapy in children and adolescents with type 1 diabetes. Curr Paediatr 1999; 9: 158-63
4. Talaulicar M, Willms B, Rosskamp R. HOE 901, a new insulin, for substitution of basal insulin requirement in type 1 diabetes [in German]. Diabetes Stoffwechsel 1996; 5: 3-6
5. Heinemann L, Linkeschova R, Rave K, et al. Time-action profile of the long-acting insulin analog insulin glargine (HOE901) in comparison with those of NPH insulin and placebo. Diabetes Care 2000 May; 23: 644-9
6. Lepore M, Pampanelli S, Fanelli C, et al. Pharmacokinetics and pharmacodynamics of subcutaneous injection of long-acting human insulin analog glargine, NPH insulin, and ultralente human insulin and continuous subcutaneous infusion of insulin lispro. Diabetes 2000 Dec; 49: 2142-8
7. Meyer BH, Scholtz HE, Pretorius SG, et al. A comparison of the pharmacodynamics (glucose lowering effect) of intravenous HOE901 and regular insulin using the euglycaemic clamp technique [abstract]. Clin Pharmacol Ther 2000 Feb; 67: 123
8. Mohideen P, Mudaliar S, Deutsch R, et al. Characterization of glucose turnover of insulin glargine in comparison with regular human insulin in healthy male subjects [abstract no. 879]. 35th Annual Meeting of the European Association for the Study of Diabetes (EASD); 1999 28 Sep-2 Oct; Brussels. Diabetologia 1999 Sep/Oct; 42 Suppl. 1: A234
9. Dagogo-Jack S, Askari H, Morrill B, et al. Physiological responses during hypoglycaemia induced by regular human insulin or a novel human, insulin glargine. Diabetes Obes Metab 2000; 2: 373-83
10. Dagogo-Jack S, Askari H, Lehner LL. Effect of glargine on glucose disposal and lipolysis in healthy and diabetic subjects [abstract 1757]. Diabetes 2000 May; 49 Suppl. 1: A412
11. Seipke G, Berchthold H, Geisen K, et al. HOE901 - a new insulin with prolonged action [abstract]. Eur J Endocrinol 1995 Apr; 132 Suppl. 1: 25
12. Bähr M, Kolter T, Seipke G, et al. Growth promoting and metabolic activity of the human insulin [GlyA21,ArgB31,ArgB32] insulin (HOE 901) in muscle cells. Eur J Pharmacol 1997 Feb 12; 320: 259-65
13. Kurtzhals P, Schaffer L, Sorensen A, et al. Correlations of receptor binding and metabolic and mitogenic potencies of insulin analogs designed for clinical use. Diabetes 2000 Jun; 49: 999-1005
14. Sandow J, Seipke G. In vitro pharmacology studies with insulin glargine and human insulin: IGF-1 receptor binding and thymidine incorporation [abstract no. 1787-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A429
15. Stammberger I, Troschau G, Donaubauer H. Insulin glargine is not carcinogenic in rats and mice [abstract no. 1788-PO]. Diabetes 2001 Jun; 50 Suppl. 2: A429
16. Luzio SD, Owens D, Evans M, et al. Comparison of the sc absorption of HOE 901 and NPH human insulin type 2 diabetic subjects [abstract]. Diabetes 1999 May; 48 Suppl. 1: 111
17. Owens DR, Coates PA, Luzio SD, et al. Pharmacokinetics of 125I-labeled insulin glargine (HOE 901) in healthy men. Diabetes Care 2000 Jun; 23: 813-9
18. Heise T, Bott S, Rave K, et al. No evidence for accumulation of HOE901 after multiple injections in type 1 diabetic patients. Diabetologia 2000; 43 Suppl. 1: A196
19. Seipke G, Sandow J, Geisen K, et al. Preclinical profile of the new long-acting insulin glargine (HOE 901) [abstract no. P1-283]. 82nd Annual Meeting of the Endocrine Society; 2000 Jun 21-24; Toronto (ON)
20. Sandow J, Seipke G, Kuerzel GU, et al. Pharmacokinetis and metabolism of insulin glargine [abstract no. PI-358]. Endocrine Society 83rd Annual Meeting; 2001 Jun 20-23; Denver (CO)
21. Hershon K, Blevins T, Donley D, et al. Lower fasting blood glucose (FBG) and less symptomatic hypoglycemia with QD insulin glargine (Lantus) compared to BID NPH in subjects with type 1 diabetes [abstract 466-P]. Diabetes 2001 Jun; 50 Suppl. 2: A116
22. Pieber TR, Eugène-Jolchine I, Derobert E, et al. Efficacy and safety of HOE 901 versus NPH insulin in patients with type 1 diabetes. Diabetes Care 2000; 23 (2): 157-62
23. Raskin P, Klaff L, Bergenstal R, et al. A 16-week comparison of the novel insulin analog insulin glargine (HOE 901) and NPH human insulin used with insulin lispro in patients with type 1 diabetes. Diabetes Care 2000 Nov; 23: 1666-71
24. Ratner RE, Hirsch IB, Neifing JL, et al. Less hypoglycemia with insulin glargine in intensive insulin therapy for type 1 diabetes. Diabetes Care 2000 May; 23: 639-43
25. Rosenstock J, Park G, Zimmerman J, et al. Basal insulin glargine (HOE 901) versus NPH insulin in patients with type 1 diabetes on multiple daily insulin regimens. Diabetes Care 2000 Aug; 23: 1137-42
26. Standl E. Results of an international, multicentred, randomised 28 week study for the comparison of glargine insulin (HOE 901) and NPH insulin in the intensified treatment (ICT) of Type 1 Diabetics [abstract no. pFr107]. Exp Clin Endocrinol Diabetes 2000; 108 Suppl. 1: 159
27. Schoenle E. Insulin glargine (HOE 901) lowers fasting blood glucose in children with type 1 diabetes mellitus without increasing the risk of hypoglycaemia [abstract no. 883]. Diabetologia 1999; 42 Suppl. 1: A235
28. Fonseca V, Bell D, Mecca T. Less symptomatic hypoglycemia with bedtime insulin glargine (Lantus) compared to bedtime NPH insulin in patients with type 2 diabetes [abstract no. 449-P]. Diabetes 2001 Jun; 50 Suppl. 2: A112
29. Massi Benedetti M. Results of a 12 month study: insulin glargine (HOE 901) in combination with oral agents (pre-EASD Symposium, Brussels) [abstract]. European Association for the Study of Diabetes; 1999 Sep: Brussels.
30. Matthews DR, Pfeiffer C. Comparative clinical trial of a new long-acting insulin (HOE901) vs. protamine insulin demonstrates less nocturnal hypoglycaemia. Multicentre HOE901 Research Group [abstract]. Diabetes 1998 May; 47 Suppl. 1: A101
31. Raskin P, Park G, Zimmerman J. The effect of HOE 901 on glycemic control in type 2 diabetes [abstract]. Diabetes 1998 May; 47 Suppl. 1: A103
32. Rosenstock J, Schwartz SL, Clark C, et al. Basal insulin therapy in type 2 diabetes: 28-week comparison of insulin glargine (HOE 901) and NPH insulin. Diabetes Care 2001 Apr; 24 (4): 631-6
33. Yki-Jarvinen H, Dressler A, Ziemen M, et al. Less nocturnal hypoglycemia and better post-dinner glucose control with bedtime insulin glargine compared with bedtime NPH insulin during insulin combination therapy in type 2 diabetes. Diabetes Care 2000 Aug; 23: 1130-6
34. Witthaus E, Stewart J, Bradley C. Treatment satisfaction and psychological well-being with insulin glargine compared with NPH in patients with type 1 diabetes. Diabetic Med 2001 Aug; 18 (8): 619-25
35. Witthaus E, Stewart J, Bradley C. Improved psychological outcomes after initiation of insulin treatment in patients with type 11 diabetes. Diabetologia 2000; 43 Suppl. 1: A205
36. Working Group. HOE 901 Retinopathy Expert Statement [Data on file]. 1999 Aug 5
37. Aventis Pharmaceuticals Inc. Prescribing information: insulin glargine [rDNA origin] injection. Kansas City (KS): Aventis Pharmaceuticals Inc., 2000 Apr
38. AHFS Drug Information. Insulin glargine. Am J Health System Pharm 2000 Nov 1; 57: 1961